Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
NCT05839002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 187
Last updated 2023-05-03
Summary
In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).
Conditions
- Neoplasm, Esophagus
- Neoplasm, Squamous Cell
Interventions
- PROCEDURE
-
nCRT
ESCC patients that recieved surgery and nCRT.
Sponsors & Collaborators
-
Shanghai Zhongshan Hospital
collaborator OTHER -
Fudan University
lead OTHER
Eligibility
- Min Age
- 40 Years
- Max Age
- 79 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-21
- Primary Completion
- 2021-12-01
- Completion
- 2023-03-15
More Related Trials
-
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
NCT05028231 ·Status: UNKNOWN
-
China Early Esophageal Cancer Cohort
NCT06515964 ·Status: RECRUITING
-
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT05740995 ·Status: RECRUITING
-
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
NCT06601309 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT02123381 ·Status: UNKNOWN ·Phase: PHASE2
-
Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer
NCT02556762 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NCT05775419 ·Status: RECRUITING ·Phase: NA
-
The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer
NCT05615103 ·Status: UNKNOWN
-
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
NCT06173986 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma
NCT02446574 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
NCT04115618 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
NCT07016724 ·Status: RECRUITING ·Phase: PHASE2
-
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
NCT07162506 ·Status: RECRUITING ·Phase: PHASE2
-
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06888531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
NCT06762158 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
NCT03734952 ·Status: RECRUITING ·Phase: NA
-
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
NCT05541445 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
NCT04764240 ·Status: COMPLETED
-
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
NCT06490003 ·Status: RECRUITING
-
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342 ·Status: RECRUITING ·Phase: PHASE1
-
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
NCT02850991 ·Status: COMPLETED ·Phase: NA
-
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
NCT05469061 ·Status: UNKNOWN ·Phase: PHASE2
-
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
NCT05323890 ·Status: UNKNOWN ·Phase: PHASE2